# Opko Health, Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Opko Health, Inc). ## Overview OPKO Health is a U.S.-based biopharmaceutical and diagnostics company with operations spanning pharmaceutical development, commercial products, laboratory testing, and product licensing. Its business includes international pharmaceutical platforms, a U.S. diagnostics laboratory business through BioReference, and partnerships that generate royalties, milestones, and other intellectual property-related revenue. ## Products & services • Diagnostic testing services through BioReference Health • 4Kscore® prostate cancer risk test • Rayaldee® for chronic kidney disease-related vitamin D deficiency • Long-acting Somatrogon (hGH-CTP) commercial platform • Pharmaceutical licensing, royalties, and milestone income • Clinical, women’s health, and specialty laboratory services - **Diagnostics and laboratory services** (45%) — Clinical, specialty, women’s health, and urology testing offered through BioReference. - **Commercial pharmaceutical products** (30%) — Marketed drug products and related international pharmaceutical operations. - **Licensing, royalties, and milestones** (20%) — Revenue from intellectual property, partner royalties, and contract milestones. - **Development-stage programs and other** (5%) — Research-stage assets, collaborations, and other non-core revenue items. - Diagnostic testing services through BioReference Health - 4Kscore® prostate cancer risk test - Rayaldee® for chronic kidney disease-related vitamin D deficiency - Long-acting Somatrogon (hGH-CTP) commercial platform - Pharmaceutical licensing, royalties, and milestone income - Clinical, women’s health, and specialty laboratory services ## Customers OPKO sells to physicians, hospitals, clinics, geneticists, correctional health facilities, and other healthcare providers that order diagnostic tests for patient care. On the pharmaceutical side, its customers and counterparties include patients, healthcare providers, distributors, and commercial partners that license or commercialize its products and intellectual property. - **Physicians and specialist practices** (primary) — Order diagnostic tests such as 4Kscore and specialty lab panels to support diagnosis and treatment decisions. - **Hospitals and clinics** (primary) — Use laboratory services for clinical chemistry, pathology, and women’s health testing. - **Healthcare payors and networks** (primary) — Influence reimbursement and network access for laboratory testing services. - **Pharmaceutical and biotech partners** (secondary) — License OPKO’s assets, pay royalties, and fund development or commercialization milestones. - **Patients** (secondary) — Ultimately receive the diagnostic and therapeutic benefit from tests and medicines, though purchasing is usually mediated by providers and payors. - Physicians ordering specialty and routine diagnostic tests - Hospitals and clinics using lab services for patient management - Urology practices using 4Kscore for prostate cancer risk assessment - Correctional and other health facilities needing laboratory testing - Pharmaceutical partners paying royalties, milestones, or license fees ## Geography OPKO has a U.S. diagnostics footprint, with BioReference serving physicians and facilities nationwide and women’s health and clinical testing concentrated in New York and New Jersey. Its pharmaceutical operations are international, with principal platforms in Spain, Ireland, Chile, and Mexico, and research and development facilities in the United States, Ireland, Israel, and Spain. - **United States** (45%) — U.S. diagnostics and corporate operations are a major part of the business. - **Europe** (30%) — Principal pharmaceutical platforms and R&D presence in Spain and Ireland. - **Latin America** (20%) — Commercial pharmaceutical operations in Chile and Mexico. - **Middle East** (5%) — R&D and operating presence in Israel. - BioReference serves U.S. physicians, hospitals, clinics, and correctional facilities - Women’s health and clinical testing are concentrated in New York and New Jersey - Principal pharmaceutical operations are in Spain, Ireland, Chile, and Mexico - R&D facilities are located in Weston, Waterford, Kiryat Gat, and Barcelona - International operations create foreign exchange and local market exposure ## Strategy OPKO’s strategy centers on combining diagnostics, commercial pharmaceuticals, and partner-driven intellectual property revenue to diversify its business base. It also relies on international pharmaceutical platforms and collaborations to extend the reach of products such as Somatrogon while using BioReference to maintain a U.S. diagnostics franchise. - **Expand specialty diagnostics** (short-term) — Specialty tests can deepen physician relationships and support differentiated lab volumes. - **Monetize partnered intellectual property** (short-term) — Royalties and milestones provide non-lab revenue tied to external commercialization success. - **Support international pharmaceutical platforms** (medium-term) — Foreign operating platforms broaden product access and create commercial scale outside the U.S. - **Advance development-stage assets and partnerships** (medium-term) — Pipeline progress can create future product revenue and licensing opportunities. - Grow diagnostics through specialty tests and new product integration - Monetize intellectual property through royalties, milestones, and contracts - Support international pharmaceutical platforms for commercial reach - Advance partnered products such as Somatrogon and other assets - Use acquisitions, licensing, and investments to add pipeline value ## Risks OPKO faces reimbursement pressure, competitive intensity, and regulatory risk across both diagnostics and pharmaceuticals. Its business also depends on successful product development, partner commercialization, patent protection, and the performance of international operations, which adds foreign exchange and impairment risk. - **Reimbursement pressure and payor consolidation** [high] — Large insurers can demand lower fees, narrower networks, or risk-sharing terms for lab services. - **Quality and laboratory performance risk** [high] — Errors in testing can lead to patient harm, lawsuits, reputational damage, and regulatory scrutiny. - **Competitive pressure** [medium] — Larger pharma and diagnostics peers have greater resources, scale, and commercialization reach. - **Regulatory and approval risk** [high] — Product development depends on FDA and other regulatory approvals and ongoing compliance. - **Foreign exchange and international operating risk** [medium] — International subsidiaries and foreign-currency exposure can affect reported revenue and cost of sales. - **Impairment risk on goodwill and intangibles** [high] — Large acquired intangible balances depend on future cash flow assumptions and product performance. - Payors can reduce reimbursement or exclude laboratories from networks - Diagnostic quality issues can trigger liability, reputational harm, or FDA action - Competition is intense in both pharmaceuticals and diagnostics - Product candidates may fail to gain market acceptance after approval - Foreign exchange and international demand affect product revenue and margins ## Accounting OPKO’s results are shaped by revenue recognition across product sales, royalties, milestones, and contract-based intellectual property arrangements, which can create timing variability. Investors should also watch goodwill, IPR&D, and intangible asset impairment because the company carries large acquired balances whose value depends on future cash flows and commercialization success. - **Revenue recognition for royalties, milestones, and IP contracts** — BARDA contract revenue, NGENLA royalties, and commercial milestones - **Goodwill and intangible asset impairment** — Diagnostics goodwill, Ireland reporting unit goodwill, IPR&D - **Foreign currency translation and transaction effects** — Chile, Mexico, Spain, and Ireland operations - **Clinical trial and license obligations** — Contractual obligations and royalty agreements - Revenue from products, royalties, milestones, and IP contracts can be uneven - Foreign currency movements affect international revenue and product costs - Goodwill and IPR&D require judgmental impairment testing - Clinical trial and license commitments may not be fully determinable - Equity-method investees can create small recurring loss recognition --- *Last updated: 2026-09-24T11:16:41.061849+00:00*